Analysis: Beta Drugs Ltd

What does Beta Drugs Ltd do?

• Beta Drugs Limited is an Indian pharmaceutical company specializing in oncology, CDMO, exports, API, and derma segments, headquartered in Panchkula, Haryana.
• The company operates through wholly owned subsidiaries: Adley Formulations Private Limited, Adley Lab Limited, and Beta Research Private Limited.
• Led by the Batra family (Rahul Batra, Chairman & Managing Director; Varun Batra, Joint Managing Director), with a focus on oncology and super-specialty pharmaceuticals.

• Branded oncology products (20% YoY growth in FY26 despite Platin supply challenges).
• CDMO services (8% YoY growth in H1 FY26, with new product additions).
• Exports (10% YoY growth in H1 FY26, with tender delays impacting FY26 performance).
• API manufacturing (14% YoY growth in H1 FY26, with PIC/S audit clearance).
• Derma and cosmetology (45% YoY growth in H1 FY26, EBITDA positive since mid-2025).

Growth thesis

Beta Drugs is a diversified pharma company specializing in branded oncology, API manufacturing, CDMO services, derma/cosmetology, and exports. Key growth drivers include the Nivian IVF acquisition (30% annual growth), 20-25 new product launches (including NDDS) by FY29, and API margin expansion from in-house KSM production. Export revenue is projected to triple to INR105-110 crores in FY27, contributing 30% of total revenue by FY30, while derma/cosmetology targets INR50-60 crores with 12-14% EBITDA margins. Vision 2030 aims for INR900+ crores revenue by 2030 through 20-25% annual growth across segments. The key execution risk is regulatory delays in EU/regulated-market dossiers (100+ pending) critical for export expansion.

Why is Beta Drugs Ltd stock rising?

• Vision 2030: aim to more than double sales to INR900+ crores in the next 3–4 years
• Own branded oncology to grow 20–25% annually for the next 3–4 years
• Exports to contribute 30% of total revenue by FY30
• Export revenue expected to grow over 50% in FY27 driven by recently awarded tenders
• Targeting ~100 new product registrations this year; over 200 dossiers submitted in last 1.5 years

Research report

Beta Drugs operates in the domestic oncology pharmaceutical market, manufacturing and marketing a range of anti-cancer drugs across solid tumour, haematology, and supportive care segments. The company ranks among the top 10 players in the domestic cytotoxic market. Its products are available across major government and private hospitals throughout India. The company was taken over by Mr Vijay Batra in 2014 from its erstwhile promoters. It is now part of the Adley group, which Mr Batra founded i...

Catalysts

capex, margin expansion, acquisition inorganic, debt reduction

Growth guidance

FY27 revenue growth guided at 20-25% annually driven by exports, branded sales, Derma, and Nivian acquisition

Management consistency

consistent